RxDoctor Payments Data

Russell Fileccia, MD

Cardiovascular Disease · Shreveport, LANPI 1164412789

Payments from drug & device makers

$7,640in general payments, 2019–2025

Across 135 payments — averaging $56.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Edwards Lifesciences$2K
  • Inari Medical, Inc.$446
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$433
  • Pfizer$128
  • Medtronic$128
  • plus $512 from 13 others

What the payments were for

  • Travel & lodging$3,87051%
  • Food & beverage$3,69148%
  • Education$801%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,640 in reported general payments places this provider in the 65th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,120,208
Medicare patients
2,163
Services billed
11,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban371$360,384
EntrestoSacubitril/Valsartan131$138,301
XareltoRivaroxaban150$121,567
MultaqDronedarone Hcl73$77,861
Repatha SureclickEvolocumab44$30,110
JardianceEmpagliflozin12$12,844
FarxigaDapagliflozin Propanediol12$9,010
Metoprolol Succinate674$8,389
Propafenone Hcl206$7,996
ClopidogrelClopidogrel Bisulfate431$4,537
Propafenone Hcl ErPropafenone Hcl13$4,139
Rosuvastatin Calcium307$3,334
Losartan Potassium405$3,265
Atorvastatin Calcium341$2,434
SotalolSotalol Hcl153$2,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$360,384371 claims
NovartisEntresto$21$138,301131 claims
Johnson & JohnsonXarelto$17$121,567150 claims
Sanofi-aventis U.S. LLCMultaq$80$77,86173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →